Dr George Garibaldi MD is a psychiatrist and neuroscientist with more than 20 years’ experience of global therapy development and medical affairs at Sandoz/Novartis, Janssen and Roche. Most recently, Dr Garibaldi served as Global Head of Neurosciences Product Development at F. Hoffmann La Roche. In this role, he developed Ocrelizumab, an antiCD20 monoclonal antibody, in primary progressive and relapsing remitting multiple sclerosis. In his different tenures, he led the global development and approval of multiple new molecular entities in various indications of psychiatry, neurodegenerative, neuroimmunological and neurodevelopmental diseases. He has published more than 100 papers in peer-reviewed journals.
Dr Garibaldi is the founder and past president of the International Society for CNS Trial Methodology and is currently the chairman of the International Society for CNS Drug Development.
Dr Garibaldi holds a medical degree (MB BcH) from Cairo University, specialized in Psychiatry and child psychiatry at Université René Descartes, Psychopharmacology at Pitié-Salpêtrièreand biostatistics at the Kremlin Bicêtrein Paris.